SALWA MOHAMEDAMAN: Open Payments
NPI 1033764659 · FRISCO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,834 in 150 payments from 20 companies in 2025. Trend: 2023 $2,233 · 2024 $2,414 · 2025 $2,834
Food & beverage: $2,834
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $443 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $349 |
| E.R. Squibb & Sons, L.L.C. | 17 | $325 |
| Janssen Pharmaceuticals, Inc | 22 | $306 |
| Neurocrine BioSciences, Inc. | 10 | $290 |
| Otsuka America Pharmaceutical, Inc. | 9 | $189 |
| Teva Pharmaceuticals USA, Inc. | 9 | $184 |
| Vanda Pharmaceuticals Inc. | 10 | $161 |
| Supernus Pharmaceuticals, Inc. | 8 | $116 |
| Alkermes, Inc. | 4 | $97 |
Products named: VRAYLAR, CAPLYTA, COBENFY, INGREZZA, REXULTI, INVEGA SUSTENNA, FANAPT, SPRAVATO.
Industry payments across TX — which companies pay providers there.
